Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: A randomized controlled trial

Clinical Infectious Diseases

Volumn 60, Issue 7, 2015, Pages 1026-1032

  Winston, Alan ^a   Amin, Janaki ^b   Clarke, Amanda ^c   Else, Laura ^d   Amara, Alieu ^d   Owen, Andrew ^d   Barber, Tristan ^e   Jessen, Heiko ^f   Avinghsanon, Anchalee ^c   Chetchotisakd, Ploenchan ^g   Khoo, Saye ^d   Cooper, David A ^b   Emery, Sean ^b   Puls, Rebekah ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^f Special Medical Practice   (Germany)

^g KHON KAEN UNIVERSITY   (Thailand)

Author keywords

CSF; efavirenz; HIV; pharmacogenomics; pharmacokinetics

Indexed keywords

7 HYDROXY EFAVIRENZ; 8 HYDROXY EFAVIRENZ; ANTIVIRUS AGENT; DRUG METABOLITE; EFAVIRENZ; PLACEBO; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EXPOSURE; DRUG SAFETY; FEMALE; GENOTYPE; HUMAN; IC50; LIMIT OF DETECTION; LUMBAR PUNCTURE; MALE; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; VIRUS REPLICATION; WILD TYPE; CHEMISTRY; HIV INFECTIONS;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CEREBROSPINAL FLUID; FEMALE; HIV INFECTIONS; HUMANS; MALE;

EID: 84926672334     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu976     Document Type: Article

References (24)

1. Cusini A, Vernazza PL, Yerly S, et al. Higher CNS penetration-effectiveness of long-Term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr 2013; 62:28-35.
2. Rawson T, Muir D, Mackie NE, Garvey LJ, Everitt A, Winston A. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting. J Infect 2012; 65:239-45.
3. Vassallo M, Durant J, Biscay V, et al. Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIVassociated neurocognitive disorders?. AIDS 2014; 28:493-501.
4. Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol 2012; 18:388-99.
5. Puls R, Amin J, Losso M, et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, noninferiority trial. Lancet 2014; 383:1474-82.
6. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306:287-300.
7. Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos 2010; 38:1218-29.
8. Avery LB, VanAusdall JL, Hendrix CW, Bumpus NN. Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid. Drug Metab Dispos 2013; 41:422-9.
9. Tovar-y-Romo LB, Bumpus NN, Pomerantz D, et al. Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther 2012; 343:696-703.
10. Best BM, Koopmans PP, Letendre SL, et al. Efavirenz concentrations in CSF exceed IC50 for wild-Type HIV. J Antimicrob Chemother 2011; 66:354-7.
11. Amara AB, Tija J, Dutton J, Else LJ, Back DJ, Khoo S. Development and validation of a HPLC-MS/MS assay to quantify the antiretroviral (ARV) drug efavirenz and its major metabolites in plasma. In: Annual Meeting of the British Mass Spectrometry Society (BMSS), Cardiff, UK, 2011.
12. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-400.
13. Sarfo FS, Zhang Y, Egan D, et al. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J Antimicrob Chemother 2014; 69:491-9.
14. Mora-Peris B, Watson V, Vera JH, et al. Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapinecontaining combined antiretroviral therapy. J Antimicrob Chemother 2014; 69:1642-7.
15. Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample. Br J Clin Psychol 2005; 44:227-39.
16. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143:714-21.
17. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34:220-33.
18. Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011; 76:1403-9.
19. Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med 2014; 161:1-10.
20. Brandmann M, Nehls U, Dringen R. 8-Hydroxy-efavirenz, the primary metabolite of the antiretroviral drug efavirenz, stimulates the glycolytic flux in cultured rat astrocytes. Neurochem Res 2013; 38: 2524-34.
21. Harjivan SG, Wanke R, Ferreira da Silva JL, Marques MM, Antunes AM. The phenolic metabolites of the anti-HIV drug efavirenz: evidence for distinct reactivities upon oxidation with Fremy's salt. Eur J Med Chem 2014; 74:7-11.
22. Ngaimisi E, Mugusi S, Minzi OM, et al. Long-Term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 2010; 88:676-84.
23. Miksys SL, Tyndale RF. Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 2002; 27:406-15.
24. Ashraf T, Robillard K, Chan GN, Bendayan R. Role of CNS transporters in the pharmacotherapy of HIV-1 associated neurological disorders. Curr Pharm Des 2014; 20:1543-63.